Matthew Galsky

Matthew Galsky is a bladder cancer specialist who has focused on improving treatment for cisplatin-ineligible patients, a major unmet need in urothelial carcinoma. He developed criteria for defining cisplatin ineligibility that are now widely used in clinical trials and practice. His research has advanced understanding of immunotherapy in the first-line setting for cisplatin-ineligible patients and identified predictive biomarkers. He co-leads the Bladder Cancer Advocacy Network Scientific Advisory Board and multiple cooperative group trials.